Visual changes secondary to initiation of amiodarone: A case report and review involving ocular management in cardiac polypharmacy

Optometry

Volumn 73, Issue 2, 2002, Pages 113-121

  Castells, David D ^a   Teitelbaum, Bruce A ^a   Tresley, David J ^b  

^a ILLINOIS COLLEGE OF OPTOMETRY   (United States)

^b Chicago Eye Institute   (United States)

Author keywords

Amiodarone; Digoxin; Dyschromatopsia; Ocular toxicity; Optic neuropathy

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

AGED; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART ARRHYTHMIA; HUMAN; MALE; PATHOPHYSIOLOGY; POLYPHARMACY; REVIEW; VISUAL ACUITY; VISUAL DISORDER;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; HUMANS; MALE; POLYPHARMACY; VISION DISORDERS; VISUAL ACUITY;

EID: 2242490029     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Naccarelli GV, Wolbrette DL, Dell'Orfano JT, et al. Amiodarone: what have we learned from clinical trials? Clin Cardiol 2000;23:73-82.
2. Harris L, McKenna WJ, Rowland E, et al. Side effects and possible contraindications of amiodarone use. Am Heart J 1983;106(4 pt 2):916-22.
3. Duff GR, Fraser AG. Impairment of colour vision associated with amiodarone keratopathy. Acta Ophthalmol (Copenh) 1987;65:48-52.
4. Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998;42:360-6.
5. Nielsen CE, Andreasen F, Bjerregaard P. Amiodarone induced cornea verticillata. Acta Ophthalmol (Copenh) 1983;61:474-80.
6. Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 1982;66:676-9.
7. Pollak PT. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol 1999;84(9A):37R-45R.
8. Ingram DV. Ocular effects in long-term amiodarone therapy. Am Heart J 1983;106(4 Pt 2):902-5.
9. Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999;127:610-2.
10. Sreih AG, Schoenfeld MH, Marieb MA. Optic neuropathy following amiodarone therapy. Pacing Clin Electrophysiol 1999;22:1108-10.
11. Feiner LA, Younge BR, Kazmier FJ, et al. Optic neuropathy and amiodarone therapy. Mayo Clin Proc 1987;62:702-17.
12. Duncker GI, Kisters G, Grille W. Prospective, randomized, placebo-controlled, double-blind testing of colour vision and electroretinogram at therapeutic and subtherapeutic digitoxin serum levels. Ophthalmologica 1994;208:259-61.
13. Aronson JK, Ford AR. The use of colour vision measurement in the diagnosis of digoxin toxicity. Q J Med 1980;49:273-82.
14. Chuman MA, LeSage J. Color vision deficiencies in two cases of digoxin toxicity. Am J Ophthalmol 1985;100:682-5.
15. ASHP. Cardiac drugs. In: Drug Information 2001. Bethesda, Md.: American Society of Health-system Pharmacists, 2001:1500-11.
16. Massaro FJ, Moulton JS, Linkewich JA, et al. Scotomas secondary to digoxin intoxication. Drug Intell Clin Pharm 1983;17:368-70.
17. Fraunfelder F, Fraunfelder, FW. Drug-induced ocular side effects, 5th ed. Boston: Butterworth-Heinemann, 2001:273-8, 318-25.
18. Piltz JR, Wertenbaker C, Lance SE, et al. Digoxin toxicity. Recognizing the varied visual presentations. J Clin Neuroophthalmol 1993;13:275-80.
19. Duncker G, Horst HA, Kolenda KD, et al. Disorders of color perception in subtoxic and toxic digoxin and serum digoxin concentrations. Klin Monatsbl Augenheilkd 1988; 193:622-6.
20. Greene HL, Graham EL, Werner JA, et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J Am Coll Cardiol 1983;2:1114-28.
21. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J 1985;109(5 Pt 1): 975-83.
22. Orlando RG, Dangel ME, Schaal SF. Clinical experience and grading of amiodarone keratopathy. Ophthalmology 1984;91:1184-7.
23. Dolan BJ, Flach AJ, Peterson JS. Amiodarone keratopathy and lens opacities. J AM OPTOM ASSOC 1985;56:468-70.
24. Hyatt RH, Sinha B, Vallon A, et al. Noncardiac side-effects of long-term oral amiodarone in the elderly. Age Ageing 1988;17:116-22.
25. Flach AJ, Dolan BJ. Progression of amiodarone induced cataracts. Doc Ophthalmol 1993;83:323-9.
26. Flach AJ, Dolan BJ, Sudduth B, et al. Amiodarone-induced lens opacities. Arch Ophthalmol 1983;101:1554-6.
27. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984;9:136-56.
28. Nazarian SM, Jay WM. Bilateral optic neuropathy associated with amiodarone therapy. J Clin Neuroophthalmol 1988;8:25-8.
29. Seemongal-Dass RR, Spencer SR. Bilateral optic neuropathy linked with amiodarone [letter]. Eye 1998;12(Pt 3a):474-7.
30. Dewachter A, Lievens H. Amiodarone and optic neuropathy. Bull Soc Belge Ophtalmol 1988;227:47-50.
31. Ferreiro JL, Isern Longares JA, Ramon Moya AF. Optic neuropathy caused by amiodarone. Neurologia 1990;5:160-3.
32. Belec L, Davila G, Bleibel JM, et al. Bilateral optic neuropathy during prolonged treatment with amiodarone (letter). Ann Med Interne 1992;143:349-50.
33. Eryilmaz T, Atilla H, Batloglu F, et al. Amiodarone-related optic neuropathy. Jpn J Ophthalmol 2000;44:565-568.
34. Speicher MA, Goldman MH, Chrousos GA. Amiodarone optic neuropathy without disc edema. J Neuroophthalmol 2000;20:171-2.
35. Palimar P, Cota N. Bilateral anterior ischaemic optic neuropathy following amiodarone [letter]. Eye 1998;12(Pt 5): 894-6.
36. Gittinger JW Jr., Asdourian GK. Papillopathy caused by amiodarone. Arch Ophthalmol 1987;105:349-51.
37. Sedwick LA. Getting to the heart of visual loss: when cardiac medication may be dangerous to the optic nerves [clinical conference]. Surv Ophthalmol 1992;36:366-72.
38. Lullmann H, Lullmann-Rauch R, Wassermann O. Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol 1975;4:185-218.
39. Adams PC, Holt DW, Storey GC, et al. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 1985;72:1064-75.
40. Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. Am Heart J 1983;106(4 Pt 2):840-7.
41. Mansour AM, Puklin JE, O'Grady R. Optic nerve ultrastructure following amiodarone therapy. J Clin Neuroophthalmol 1988;8:231-7.
42. Ghosh M, McCulloch C. Amiodarone-induced ultrastructural changes in human eyes. Can J Ophthalmol 1984; 19:178-86.
43. Haug SJ, Friedman AH. Identification of amiodarone in corneal deposits. Am J Ophthalmol 1991;111:518-20.
44. Hobley A, Lawrenson J. Ocular adverse effects to the therapeutic administration of digoxin. Ophthalmic Physiol Opt 1991;11:391-3.
45. Staff DfAC. Cardiac glycosides. In: Drug facts and comparisons 2000, 54th ed. St. Louis: Facts and Comparisons, 2000:397-401.
46. Lalonde RL, Pao D. Correlation coefficient versus prediction error in assessing the accuracy of digoxin dosing methods. Clin Pharm 1984;3:178-83.
47. Robertson DM, Hollenhorst RW, Callahan JA. Receptor function in digitalis therapy. Arch Ophthalmol 1966;76:852-7.
48. Sprague HB, et al. Disturbances of vision caused by digitalis preparations. JAMA 1925;85.
49. Closson RG. Visual hallucinations as the earliest symptom of digoxin intoxication. Arch Neurol 1983;40:386.
50. Volpe BT, Soave R. Formed visual hallucinations as digitalis toxicity. Ann Intern Med 1979;91:865-6.
51. Gelfand ML. Visual symptoms after digoxin therapy. JAMA 1951;147:1231-3.
52. Robertson DM, Hollenhorst RW, Callahan JA. Ocular manifestations of digitalis toxicity. Discussion and report of three cases of central scotomas. Arch Ophthalmol 1966;76:640-5.
53. Sykwoski P. Digitoxin intoxication resulting in retrobulbar optic neuritis. Am J Ophthalmol 1949;32:572-4.
54. Mermoud A, Safran AB, de Stoutz N. Pain upon eye movement following digoxin absorption. J Clin Neuroophthalmol 1992;12:41-2.
55. Ochs HR, Greenblatt DJ, Harmatz JS, et al. Serum digoxin concentrations and subjective manifestations of toxicity. Pharmacology 1980;20:149-54.
56. Rietbrock N, Alken RG. Color vision deficiencies: a common sign of intoxication in chronically digoxin-treated patients. J Cardiovasc Pharmacol 1980;2:93-9.
57. Duncker G, Krastel H. Ocular digitalis effects in normal subjects. Lens Eye Toxic Res 1990;7:281-303.
58. Haustein KO, Oltmanns G, Rietbrock N, et al. Differences in color vision impairment caused by digoxin, digitoxin, or pengitoxin. J Cardiovasc Pharmacol 1982;4:536-41.
59. Rietbrock N, Alken RG. Disorders of the ability to distinguish colors during digitalis therapy (author's transi.). MMW Munch Med Wochenschr 1980;122:1624-6.
60. Smith JL, Michtavage R. The ocular effects of topical digitalis. Am J Ophthalmol 1963;56:889-94.
61. Madreperla SA, Johnson MA, O'Brien TP. Corneal ednothelial dysfunction in doigoxin toxicity. Am J Ophthalmol 1992;113:211-2.
62. Lissner W, Greenlee JE, Cameron JD, et al. Localization of tritiated digoxin in the rat eye. Am J Ophthalmol 1971;72:608-14.
63. Duncker G. On the ocular distribution of cardiac glycosides in guinea pigs following acute administration. Graefe's Arch Clin Ophthalmol 1989;227:55-9.
64. Weleber RG, Shults WT. Digoxin retinal toxicity. Clinical and electrophysiological evaluation of a cone dysfunction syndrome. Arch Ophthalmol 1981;99:1568-72.
65. Bonting SL. Physiological chemistry of the eye. A review of papers published during 1964. Arch Ophthalmol 1965;74:561-78.
66. Madreperla SA, Johnson MA, Nakatani K. Electrophysiologic and electroretinographic evidence for photoreceptor dysfunction as a toxic effect of digoxin. Arch Ophthalmol 1994;112:807-12.
67. Vrobel TR, Miller PE, Mostow ND, et al. A general overview of amiodarone toxicity: its prevention, detection, and management. Prog Cardiovasc Dis 1989;31:393-426.